Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease

GOM Therapeutics正在开发一种一流的治疗方法，用于治疗一种常见的遗传性神经血管疾病，目前尚无治疗方法。这种疾病是一种进行性慢性成人发病性疾病，可导致痴呆、身体残疾和过早死亡。这种遗传性疾病严重影响患者及其家人的生活。我们正在采取一种高度创新的方法，建立在最近的重要科学进展之上。我们的项目旨在评估为我们的药物发现过程提供重要起始组件的可行性。该项目代表了可能为服务不足的患者群体带来新疗法的重要一步。

GOM Therapeutics is developing a first-in-class therapeutic for a common genetic neurovascular disease with no existing treatment. The disease is a progressive, chronic adult-onset disorder that leads to dementia, physical disability and premature death. This heritable condition significantly affects the lives of patients and their families. We are taking a highly innovative approach, building on important recent scientific advances.Our project aims to assess the feasibility of making an important starting component for our drug discovery process. This project represents an important step in potentially bringing a novel therapy to an underserved group of patients.